A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex
AIDS Dementia Complex, HIV Infections
About this trial
This is an interventional treatment trial for AIDS Dementia Complex focused on measuring AIDS Dementia Complex, Zidovudine, Stavudine, Reverse Transcriptase Inhibitors
Eligibility Criteria
Inclusion Criteria You may be eligible for this study if you: Are HIV-positive. Are at least 13 years old (need consent if under 18). Have AIDS Dementia Complex. Have been on a stable anti-HIV drug regimen for at least 8 weeks prior to study entry. Agree to use effective methods of birth control during the study. Are available for at least 16 weeks of study. Exclusion Criteria You will not be eligible for this study if you: Have ever taken d4T. Have a neurological (brain/spinal cord) disease, such as chronic seizures or head injury, or certain other conditions that would interfere with your ability to complete the study. Are pregnant or breast-feeding. Abuse alcohol or drugs. Have peripheral neuropathy or a newly diagnosed AIDS-defining infection that requires treatment at the time of study enrollment. Have received certain medications. Cannot take medications by mouth. Have severe diarrhea for at least 7 days in a row within 30 days prior to study entry.
Sites / Locations
- HIV Neurobehavioral Research Ctr
- AIDS ReSEARCH Alliance
- Mount Sinai Hosp
- National Centre in HIV Epidemiology and Clinical Research
- Charing Cross and Westminster Med School